



## Godavari Biorefineries Ltd

Dated: July 22, 2025

The Manager  
Listing Department  
National Stock Exchange of India Limited  
Exchange Plaza, C-1, Block G,  
Bandra Kurla Complex, Bandra (E),  
Mumbai – 400 051

The Manager  
Listing Department  
BSE Limited  
Phiroze Jeejeebhoy Tower,  
Dalal Street  
Mumbai-400001

**Script Symbol:** GODAVARIB

**Script Code:**544279

**Sub: Press Release**

Dear Sir / Madam,

Pursuant to regulation 30 of SEBI (Listing Obligation and Disclosure Requirements) Regulation, 2015, please find enclosed press release titled “**Godavari Biorefineries Secures Chinese Patent for Breakthrough Anti-Cancer Molecule for use in the Treatment of Cancer**”

This is for your information and records.

Thanking you,  
Yours faithfully

**For Godavari Biorefineries Limited**

**Manoj Jan**  
**Company Secretary & Compliance Officer**  
**Membership No.F-7998**

MANOJ  
JAIN

Digitally signed by MANOJ JAIN  
Date: 2025.07.22 11:46:00 +05'30'



## **Godavari Biorefineries Secures Chinese Patent for Breakthrough Anti-Cancer Molecule for use in the Treatment of Cancer**

**Mumbai, July 22, 2025:** Godavari Biorefineries Limited (BSE: 544279 | NSE: GODAVARIB), through its clinical-stage biotech division **Sathgen Therapeutics**, has been granted a patent by the **China National Intellectual Property Administration (CNIPA)**, China's patent and trademark office for its novel anti-cancer molecule - **HYDROXY-1,4-NAPHTHALENEDIONE**.

This patent covers a novel class of compounds that have exhibited strong inhibitory effects on cancer and cancer stem cells in vitro studies. These compounds have demonstrated significant efficacy against multiple cancer cell types, including breast and prostate cancer

"Our focus on original, high-quality science continues to guide our journey beyond green chemistry into life sciences," said **Dr Sangeeta Srivastava, Executive Director, Godavari Biorefineries Limited**. "This Chinese patent reinforces the promise of our lead molecule and the vital work being done by our team at Sathgen Therapeutics to develop innovative therapies for some of the most pressing medical needs worldwide."

Godavari Biorefineries has established a global presence, exporting to over 20 countries and maintaining strong linkages with international research and development networks. The company's clinical-stage biotech division, Sathgen Therapeutics, is at the forefront of advancing novel cancer and antiviral therapies. With a lead molecule undergoing clinical trials and global patent protection, GBL is deepening its focus in translational research that addresses some of the world's most urgent health challenges.

**About Godavari Biorefineries Limited (GBL):** (BSE: Script Code 544279 | NSE: GODAVARIB) Godavari Biorefineries Limited is a leader in the renewable chemicals and biofuels industry, dedicated to creating sustainable solutions that contribute to a circular economy. Listed on the BSE Limited (BSE) and the National Stock Exchange of India Limited (NSE), GBL has a legacy of innovation and a commitment to sustainability, driving progress in renewable energy and green chemistry. For more information about Godavari Biorefineries, please visit [www.godavaribiorefineries.com](http://www.godavaribiorefineries.com).

**Media Contact:**

Pushpendra Dhansoia

Corporate Communications - GBL

Email: [dhansoia.pushpendra@somaiya.com](mailto:dhansoia.pushpendra@somaiya.com)

Phone: +91 9029037173